Kenvue Inc. (NYSE:KVUE) Receives Average Rating of “Hold” from Brokerages

Shares of Kenvue Inc. (NYSE:KVUE) have received an average recommendation of “Hold” from the thirteen ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $22.64.

KVUE has been the topic of several research reports. JPMorgan Chase & Co. upped their price target on shares of Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Citigroup decreased their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. UBS Group upped their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th.

Kenvue Price Performance

NYSE:KVUE opened at $21.72 on Thursday. Kenvue has a one year low of $17.67 and a one year high of $23.33. The company has a market cap of $41.59 billion, a P/E ratio of 27.85, a P/E/G ratio of 2.07 and a beta of 1.38. The firm’s fifty day moving average price is $19.41 and its two-hundred day moving average price is $19.52. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.28 by $0.04. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. During the same period in the previous year, the company earned $0.32 earnings per share. The company’s quarterly revenue was down .3% on a year-over-year basis. Equities analysts expect that Kenvue will post 1.13 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, August 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.78%. This is a boost from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s dividend payout ratio is 105.13%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in KVUE. Manchester Capital Management LLC increased its position in Kenvue by 80.8% during the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares during the period. Pacific Capital Wealth Advisors Inc. acquired a new stake in shares of Kenvue during the 4th quarter worth approximately $28,000. Mather Group LLC. acquired a new stake in shares of Kenvue during the 1st quarter worth approximately $28,000. Oakworth Capital Inc. acquired a new stake in shares of Kenvue during the 1st quarter worth approximately $31,000. Finally, Riverview Trust Co acquired a new stake in shares of Kenvue during the 1st quarter worth approximately $33,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.